Literature DB >> 24243989

How to screen obese children at risk for type 2 diabetes mellitus?

Marloes P van der Aa1, Soulmaz Fazeli Farsani, Lisa A J Kromwijk, Anthonius de Boer, Catherijne A J Knibbe, Marja M J van der Vorst.   

Abstract

BACKGROUND: Recommended screening to identify children at risk for diabetes and its precursors impaired glucose tolerance (IGT) and insulin resistance (IR) is fasted plasma glucose (FPG). This study evaluates the added value of fasted plasma insulin (FPI).
METHODS: This study analyzed routinely collected data of an oral glucose tolerance test (OGTT) of 311 obese children (age 10.8 ± 3.2 years). Diabetes and IGT were defined according to the American Diabetes Association criteria, IR as homeostasis model assessment (HOMA)-IR ≥3.4.
RESULTS: Cases diagnosed with an OGTT if FPG ≥5.6 mmol/L, compared with an OGTT performed if FPG ≥5.6 mmol/L or HOMA-IR ≥3.4, were, respectively, 4 (80%) versus 5 (100%) with diabetes, 7 (28%) versus 16 (64%) with IGT, and 0 (0%) versus 93 (100%) with IR.
CONCLUSIONS: Screening with FPG and FPI has equal burden compared with screening with FPG alone, identifies all patients with diabetes, and identifies more patients with precursors of diabetes.

Entities:  

Keywords:  diabetes mellitus; insulin; obesity; screening

Mesh:

Substances:

Year:  2013        PMID: 24243989     DOI: 10.1177/0009922813509480

Source DB:  PubMed          Journal:  Clin Pediatr (Phila)        ISSN: 0009-9228            Impact factor:   1.168


  8 in total

1.  Serum hepcidin levels and iron metabolism in obese children with and without fatty liver: case-control study.

Authors:  Fatih Demircioğlu; Gökhan Görünmez; Emine Dağıstan; Sevil Bilir Göksügür; Mervan Bekdaş; Mehmet Tosun; Betül Kızıldağ; Erol Kısmet
Journal:  Eur J Pediatr       Date:  2014-02-07       Impact factor: 3.183

Review 2.  Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia.

Authors:  Nicola Ferri; Massimiliano Ruscica
Journal:  Endocrine       Date:  2016-04-01       Impact factor: 3.633

3.  Long-term metformin treatment in adolescents with obesity and insulin resistance, results of an open label extension study.

Authors:  Y E Lentferink; M P van der Aa; E G A H van Mill; C A J Knibbe; M M J van der Vorst
Journal:  Nutr Diabetes       Date:  2018-09-10       Impact factor: 5.097

4.  Effect of Physical Activity and Nutrition Education on Body Mass Index, Blood Pressure and Biochemical Variables in Overweight and Obese Adolescents.

Authors:  Jeanne Grace; Chara Biggs; Alden Naicker; Sarah Moss
Journal:  Ann Glob Health       Date:  2021-01-25       Impact factor: 2.462

5.  A Follow-up Study on BMI-SDS and Insulin Resistance in Overweight and Obese Children at Risk for Type 2 Diabetes Mellitus.

Authors:  Soulmaz Fazeli Farsani; Marloes P van der Aa; Catherijne A J Knibbe; Anthonius de Boer; Marja M J van der Vorst
Journal:  Glob Pediatr Health       Date:  2015-01-19

6.  Acute Activation of Metabolic Syndrome Components in Pediatric Acute Lymphoblastic Leukemia Patients Treated with Dexamethasone.

Authors:  Lidewij T Warris; Erica L T van den Akker; Marc B Bierings; Cor van den Bos; Christian M Zwaan; Sebastiaan D T Sassen; Wim J E Tissing; Margreet A Veening; Rob Pieters; Marry M van den Heuvel-Eibrink
Journal:  PLoS One       Date:  2016-06-30       Impact factor: 3.240

7.  Predictors of Insulin Resistance in Children versus Adolescents with Obesity.

Authors:  Yvette E Lentferink; Marieke A J Elst; Catherijne A J Knibbe; Marja M J van der Vorst
Journal:  J Obes       Date:  2017-12-10

8.  Crucial Role of the SH2B1 PH Domain for the Control of Energy Balance.

Authors:  Anabel Flores; Lawrence S Argetsinger; Lukas K J Stadler; Alvaro E Malaga; Paul B Vander; Lauren C DeSantis; Ray M Joe; Joel M Cline; Julia M Keogh; Elana Henning; Ines Barroso; Edson Mendes de Oliveira; Gowri Chandrashekar; Erik S Clutter; Yixin Hu; Jeanne Stuckey; I Sadaf Farooqi; Martin G Myers; Christin Carter-Su
Journal:  Diabetes       Date:  2019-08-22       Impact factor: 9.461

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.